Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05733689
Other study ID # 1977
Secondary ID UCI 21-191
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date February 2025
Est. completion date February 2026

Study information

Verified date February 2024
Source University of California, Irvine
Contact Chao Family Comprehensive Cancer Center University of California
Phone 1-877-827-8839
Email ucstudy@uci.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a ctDNA assay (test) result to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date February 2026
Est. primary completion date February 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must have histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEA). Other GE histologies which are treated per NCCN guidelines for neoadjuvant treatment are eligible. - Must have Stage IB, II or Stage III GEA eligible for (neo)adjuvant doublet or triplet chemotherapy for up to 6 months. - Must have baseline ctDNA positive assay (tested by Signatera MRD assay) prior to initiation of neoadjuvant chemotherapy. Patients who are otherwise eligible may start per protocol treatment if ctDNA result is not available at the time of initiation of systemic therapy. However, once the results is available, they can only remain on study if the ctDNA is positive. - Age = 18 years Because the safety or efficacy of neoadjuvant chemotherapy for LGEA has not been tested or established for patients <18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable. - Performance status: ECOG performance status =2 - Life expectancy of greater than 6 months - Adequate organ and marrow function as defined below: 1. leukocytes = 3,000/mcL 2. absolute neutrophil count = 1,500/mcL 3. platelets = 80,000/mcl 4. total bilirubin within normal institutional limits 5. AST(SGOT)/ALT(SPGT) = 5 X institutional upper limit of normal 6. creatinine <2 X ULN - Docetaxel can cause fetal harm and irinotecan is known to be teratogenic. Since these compounds are part of the treatment regimens, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 1. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: 1. Has not undergone a hysterectomy or bilateral oophorectomy; or 2. Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). - Ability to understand and the willingness to sign a written informed consent. 1. Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial. Exclusion Criteria: - Patients may not be receiving any other investigational agents. - Patients with known metastases from GEA. - History of allergic reactions attributed to agents used in study. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - History of another primary cancer which requires active treatment or is expected to require treatment within 12 months after enrollment. - Inability to comply with study and follow-up procedures as judged by the Investigator. - Patients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ctDNA Blood Test
Blood will be collected for ctDNA testing
Combination Product:
FLOT
Oxaliplatin 85 mg/m2 IV on Day 1 Docetaxel 50 mg/m2 IV on Day 1 Leucovorin 200 mg/m2 IV on Day 1 Fluorouracil 2600 mg/m2 continuous infusion over 24 hours daily on Day 1 Every 14 Days
FOLFOX
Oxaliplatin 85 mg/m2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 Fluorouracil 400 mg/m2 IV Push on Day 1 Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days
FOLFIRI
Irinotecan 180 mg/m2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 Fluorouracil 400 mg/m2 IV Push on Day 1 Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days
FOLFIRINOX
Oxaliplatin 85 mg/m2 IV on Day 1 Irinotecan 150 mg/m2 IV on Day 1 Leucovorin 200 mg/m2 IV on Day 1 Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 days
PACLITAXEL with or without CARBOPLATIN
Paclitaxel 200 mg/m2 IV on Day 1 Carboplatin AUC 5 IV on day 1 Every 21 Days OR - Paclitaxel 80mg/m2 IV on Days 1,8,15 Every 28 Days
DOCETAXEL and IRINOTECAN (alone or combined)
Docetaxel 35 mg/m2 IV on Days 1 and 8 Irinotecan 50 mg/m2 IV on Days 1 and 8 Every 21 Days Docetaxel 75 mg/m2 IV on Day 1 Every 21 Days Docetaxel 150 mg/m2 IV on Day 1 Every 14 Days
Drug:
NIVOLUMAB (alone or when added to a regimen above)
240 mg IV on Day 1 every 14 days, or 360 mg IV on Day 1 every 21 days, or 480 mg IV on Day 1 every 28 days
PEMBROLIZUMAB (alone or when added to a regimen above)
200 mg IV on Day 1 every 21 days, or 400 mg IV on Day 1 every 42 days

Locations

Country Name City State
United States Chao Family Comprehensive Cancer Center, University Orange California

Sponsors (2)

Lead Sponsor Collaborator
University of California, Irvine Natera, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of completing per protocol treatment. Percent of patients who will undergo attempt at curative intent resection. Up to 3 years
Secondary Percentage of patients completing gastrectomy. Percent of patients completing gastrectomy Up to 3 years
Secondary Rate of negative ctDNA after completion of neoadjuvant treatment and within 8 weeks after surgery Percent of patients with ctDNA clearance after neoadjuvant chemotherapy and after surgery (within 6-8 weeks) 8 weeks
Secondary Rate of R0 resection R0 resection is defined as complete tumor removal with negative surgical margins. Up to 3 years
Secondary Rate of post-operative complication rate within 30 days after surgery Up to 3 years
Secondary Percentage of Grade 3-5 Adverse Events Toxicity and adverse events are based on the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 5.0. Up to 3 years
Secondary Relapse-free survival time The lead time in ctDNA detection before clinical recurrence Up to 3 years
Secondary Rate of ctDNA positive patients at diagnosis Percent of patients positive for ctDNA at diagnosis Up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05977322 - A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. Phase 1
Completed NCT00073502 - Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer Phase 2
Recruiting NCT04712721 - Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. Early Phase 1
Recruiting NCT05029882 - Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab Phase 1
Withdrawn NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Completed NCT03794128 - A Study of Personalized Neoantigen Cancer Vaccines
Active, not recruiting NCT04021108 - Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Phase 2
Not yet recruiting NCT06445972 - Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) Phase 1/Phase 2
Completed NCT01045421 - MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies Phase 1/Phase 2
Completed NCT03639714 - A Study of a Personalized Neoantigen Cancer Vaccine Phase 1/Phase 2
Completed NCT01757171 - Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma Phase 2
Recruiting NCT05152147 - A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Phase 3
Not yet recruiting NCT05986227 - The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II): Phase 1/Phase 2
Terminated NCT01182610 - Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma Phase 2
Recruiting NCT06043427 - Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma Phase 2